WhiteLab Raises $26M for AI Genomic Medicine
WhiteLab Genomics raised $26M to advance AI-designed genomic medicine delivery systems.
AI biotech is becoming more specialised, with startups moving beyond molecule discovery into delivery, validation and therapeutic execution.
What happened
WhiteLab Genomics raised a $26M Series B to accelerate its AI-driven genomic medicine platform. The company designs and validates delivery vehicles, genetic payloads and other components used in genomic medicines.
Why it matters
One of the hardest problems in genomic medicine is not just designing a therapy, but delivering it safely and effectively to the right cells. WhiteLab’s focus on delivery and validation gives it a sharper technical wedge than generic AI drug discovery.
The bigger picture
The next phase of AI-enabled life sciences will depend on platforms that connect computational design with biological proof. WhiteLab is part of that shift from software-led discovery toward experimentally grounded therapeutic development.